The increased SCLC market size is a consequence of increasing incidence, expected entry of potential premium costs of emerging therapies, and anticipating uptake of currently approved immunotherapies across 7Major Markets that will lead to more effective therapies
LAS VEGAS, Feb. 20, 2020 /PRNewswire/ -- DelveInsight has announced the addition of a new market research report on "Small Cell Lung Cancer Market Insights, Epidemiology and Market Forecast-2030" to its offerings. The report proffers in depth Small Cell Lung Cancer Market Analysis, 11 years Market Size Forecast, detailed Epidemiology analysis and 11 year Forecast, Emerging Drugs Market Uptake and information related to Leading Companies along with the Competitive Analysis edge.
Some key highlights from the report:
1. According to DelveInsight's SCLC market report, total Small Cell Lung Cancer incident cases in the 7MM were assessed to be 85,540 in 2017.
2. Among 7MM countries, the United States had the highest market size of SCLC in 2017 that accounts for approximately 48% of the total market.
3. The key drivers that are fuelling the Small Cell Lung Cancer market are the Approvals of Immune-check Point Inhibitors; Robust Pipeline with Novel Targets; Increase in the Geriatric Population that will progress the SCLC market.
4. The SCLC market research report will help clients to understand the major barriers in the SCLC market like Competition of Emerging Drugs with Chemotherapeutic Agents; High Cost of Treatment, Generic chemotherapy still the treatment for SCLC, No definite biomarkers available for progressive or the transformative form of disease, Lack of Diagnosis in the Limited Stage, Challenges in early detection of SCLC due to the lack of specific symptoms and rapid tumour growth making current approaches to screening ineffective in diagnosing patients at early disease stages.
Click here to get Small Cell Lung Cancer Market sample pages: https://www.delveinsight.com/sample-request/small-cell-lung-cancer-market
Small cell lung cancer is fast-growing lung cancer. It usually starts in bronchi. Although the cancer cells are small, they grow aggressively and create large tumors. These kinds of tumors often metastasize quickly to other parts of the body.
The Small Cell Lung Cancer Epidemiology segmentation is based on Total Incident Patient Population, Gender-specific, Stage-specific, Age-specific, and Line-wise treatment of extensive-stage SCLC.
Key findings of DelveInsight's Epidemiology model
- According to the DelveInsight market report, total Small Cell Lung Cancer incident cases in the 7MM were assessed to be 85,540 in 2017. The United States has the highest percentage of SCLC Incident cases. Among the European 5 countries, Germany had the highest SCLC incident population in 2017. Lastly, Japan accounts for 21% of the 7MM patient population of SCLC.
- Gender-Specific Epidemiology of Small Cell Lung Cancer- It was observed that the SCLC occurs more frequently in male population as compared to female. In 2017, several males were affected by the disease, i.e., 55% of the SCLC cases in the 7MM, in comparison to the females.
- Stage-specific Incidence Cases in the United States - Among the two subtypes of SCLC for the year 2017, 25% of the cases of SCLC were appeared to have limited-stage SCLC. Furthermore, for extensive-stage SCLC, the number of cases contributes to 75% of the overall SCLC cases in the country.
- Age-specific Incidence in the United States - It is estimated that approximately 34% of SCLC cases belong to age-group 65-74 years.
Small Cell Lung Cancer Treatment Market
SCLC is affecting thousands of people for which the treatment options that are approved are surgery, chemotherapy, radiation therapy and immunotherapy. SCLC treatment choice is dependent on the stage of SCLC, symptoms, age, and how quickly the disease spreads and whether patients may suffer various patterns of recurrence requiring subsequent lines of rescue therapies.
The patients who have limited-stage SCLC, chemotherapy and radiation therapy are given daily over several weeks to the chest. People with extensive-stage cancer initially receive chemotherapy for 3 to 4 months or may receive chemotherapy in combination with immunotherapy.
Click to receive a sample report on Small Cell Lung Cancer Market Forecast Trends
According to DelveInsight's analysis, among the 7MM countries, the United States had the highest market size of SCLC in 2017 that accounts for approximately 48% of the total market, contributing USD 214 million. Germany accounts for highest SCLC market share of the total EU-5 market, while, Spain accommodated the least market share.
There are few approved drugs for the management of extensive SCLC. The launch of the emerging therapies is anticipated to significantly impact the SCLC treatment scenario in the upcoming years:-
Drugs covered in the report
- Imfinzi +/- tremelimumab
- Lurbinectedin (PM01183)
- RRx-001
- Dinutuximab (Unituxin)
- Irinotecan liposome injection
- Trilaciclib (G1T28)
- Dendritic Cell-based p53 Vaccine + Nivolumab + Ipilimumab
- Guadecitabine + Carboplatin
- Iclusig (ponatinib)
And many others
The SCLC Market Key Players are:-
- AstraZenecaPharmaMar
- EpicentRx
- United Therapeutics
- Ipsen
- G1 Therapeutics
- MultiVir
- Otsuka Holdings
- Takeda
Small Cell Lung Cancer Reimbursement Outline- The reimbursement can have a positive impact both during the late stages of product development and after product launch. In the SCLC market report, the reimbursement is taken into consideration to identify economically attractive indications and market opportunities.
SCLC KOL Outlook- KOLs and SME's opinions help to understand current and emerging therapies treatment patterns. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the Small Cell Lung Cancer market trends and the unmet needs.
Get a sample report: https://www.delveinsight.com/sample-request/small-cell-lung-cancer-market
Reasons to buy
- The report will help in developing business strategies by understanding trends shaping and driving the Small Cell Lung Cancer market
- To understand the future market competition in the Small Cell Lung Cancer market and Insightful review of the key market drivers and barriers
- Organize sales and marketing efforts by identifying the best opportunities for Small Cell Lung Cancer in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
- Organize sales and marketing efforts by identifying the best opportunities for Small Cell Lung Cancer market
- To understand the future market competition in the Small Cell Lung Cancer market
Key Topics Covered:
1.Key Insights |
2.Executive Summary of Small Cell Lung Cancer |
3.SWOT Analysis for SCLC |
4.Small Cell Lung Cancer Market Overview at a Glance |
5.SCLC Disease Background and Overview |
6.Small Cell Lung Cancer Epidemiology and Patient Population |
7.United States Small Cell Lung Cancer Epidemiology |
8.EU-5 Country-wise Small Cell Lung Cancer Epidemiology |
8.1.Germany |
8.2.France |
8.3.Italy |
8.4.Spain |
8.5.United Kingdom |
9.Japan Small Cell Lung Cancer Epidemiology |
10.Small Cell Lung Cancer Current Treatment Practices |
11.Patient Journey |
12.Unmet Needs |
13.Key Endpoints in SCLC Clinical Trials |
14.SCLC Marketed Products |
14.1.Opdivo (Nivolumab): Bristol-Myers Squibb/ Ono Pharmaceutical |
14.2.Keytruda (Pembrolizumab): Merck |
14.3.Tecentriq (Atezolizumab): Hoffmann-La Roche |
15.Small Cell Lung Cancer Emerging Therapies |
15.1.Key Cross |
15.2.Imfinzi +/- tremelimumab: AstraZeneca |
15.3.Lurbinectedin (PM01183): PharmaMar |
15.4.RRx-001: EpicentRx |
15.5.Dinutuximab (Unituxin): United Therapeutics |
15.6.Irinotecan liposome injection: Ipsen |
15.7.Trilaciclib (G1T28): G1 Therapeutics |
15.8.Dendritic Cell-based p53 Vaccine + Nivolumab + Ipilimumab: MultiVir |
15.9.Guadecitabine + Carboplatin: Otsuka Holdings |
15.10.Iclusig (ponatinib): Takeda |
16.Conjoint Analysis of Small Cell Lung Cancer Therapies |
17.Small Cell Lung Cancer Seven Major Market Analysis |
18.United States Small Cell Lung Cancer Market Size |
19.EU-5 SC:LC Market Size |
19.1.Germany Small Cell Lung Cancer Market Size |
19.2.France SCLC Market Size |
19.3.Italy Small Cell Lung Cancer Market Size |
19.4.Spain SCLC Market Size |
19.5.United Kingdom Small Cell Lung Cancer Market Size |
20.Japan SCLC Market Size |
21.Market Access and Reimbursement Scenario of SCLC Therapies |
22.Small Cell Lung Cancer Market Drivers |
23.SCLC Market Barriers |
24.Appendix |
25.Disclaimer |
26.DelveInsight Capabilities |
27.About DelveInsight |
Request a Webex Demo to get a walk-through of the report: https://www.delveinsight.com/sample-request/small-cell-lung-cancer-market
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Contact us:
Shruti Thakur
info@delveinsight.com
+91-9650213330
DelveInsight
Related Reports:-
- Small Cell Lung Cancer Epidemiology Forecast to 2030 - The DelveInsight's Small Cell Lung Cancer epidemiology report gives a thorough understanding of the Small Cell Lung Cancer by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also proffers treatment algorithms and treatment guidelines for Small Cell Lung Cancer in the US, Europe, and Japan. The report covers the detailed information of the Small Cell Lung Cancer epidemiology scenario in seven major countries (US, EU5, and Japan).
Logo: https://mma.prnewswire.com/media/776895/DelveInsight_Logo.jpg
